Hamburg, Germany 05 April 2017: Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept.- read more
Hamburg, Germany - 31 March 2017: Evotec AG today announced that its partner Forge Therapeutics has received a research award from CARB-X of $ 8.8 m to advance its novel Gram-negative antibiotic programme targeting LpxC for the treatment of bacterial infections.- read more
Hamburg, Germany, 28 March 2017: Evotec AG today announced its financial results and corporate updates for the fiscal year ended 31 December 2016.- read more
Hamburg, Germany, 21 February 2017:
Evotec AG is pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery partnership with Oxford University, has made its first wave of awards, backing projects targeting cardiovascular diseases and infectious diseases.
Hamburg, Germany, 09 February 2017:
Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash.
Hamburg, Germany - 26 January 2017: Evotec AG today announced that Cyprotex, a company wholly owned by Evotec AG, has completed the relocation of its UK operations from Macclesfield to Alderley Park.- read more